Program
Thrombopoietin Receptor Agonist
Also written as “thrombopoietin receptor agonist (TPO-RA)” and “PN20 treatment”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic, led by 2 companies.
Drug pageThrombopoietin Receptor Agonist: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Peg-Bio Biopharmits history only | 10 open or running | phase 1since Mar 11, 2025 | Mar 11, 2025 | none ahead |
| Novartisits history only | 11 open or running | phase 2since Feb 12, 2026 | Feb 12, 2026 | Jan 18, 2029phase 2 · NCT07421167 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 25, 2022Named thrombopoietin receptor agonistINNProposed as its International Nonproprietary Name in WHO's List 126
- Mar 11, 2025First study: phase 1 study in Purpura, Thrombocytopenic, IdiopathicNew to Chongqing Peg-Bio BiopharmChongqing Peg-Bio Biopharm · NCT06880081 · 12 enrolled · China
- Feb 12, 2026Novartis’s first study: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNew to NovartisNovartis · NCT07421167 · 164 planned · United States
Ahead
- Jan 18, 2029Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT07421167
TargetBeta
“Any agent that binds to and activates the thrombopoietin (TPO) receptor.”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07421167Purpura, Thrombocytopenic, Idiopathic · United States | 2 | Recruiting | Novartis | Jan 18, 2029 | 164 |
| NCT06880081Purpura, Thrombocytopenic, Idiopathic · China | 1 | Completed | Chongqing Peg-Bio Biopharm | Feb 14, 2026 | 12 |
How it is read
Names in the registry
- “thrombopoietin receptor agonist (TPO-RA)”, 1 entry
- “PN20 treatment”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.